文献速递腹部技术与安全CT

宽探测器CT灌注成像在胰腺导管腺癌常规分期与再分期检查中应用的可行性

Feasibility of wide detector CT perfusion imaging performed during routine staging and restaging of pancreatic ductal adenocarcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2020-10-20

本研究评估在160 mm宽覆盖256排CT常规多期增强扫描中同期行CT灌注成像的可行性,共纳入57例胰腺导管腺癌患者。灌注采集未影响标准图像诊断质量,并获得肿瘤与正常胰腺的血流量、血容量及渗透表面乘积等定量参数。作者结论认为在宽探测器CT上增加灌注采集可行,不增加检查时间或费用,所得灌注参数与现有专用灌注方案文献相当。

要点

  • 在常规多期胰腺CT中同期行灌注采集,标准图像诊断质量未受影响。
  • 肿瘤中心血流量平均20.8 ml/100 g/min,明显低于正常胰腺的90.8 ml/100 g/min。
  • 灌注采集平均SSDE为57 mGy,作者称该方案不增加检查时间或费用。

核心结论

  • 在宽探测器256排CT上,于常规胰腺CT方案中增加灌注采集是可行的,可在保持标准诊疗检查诊断质量的同时提供定量信息。
  • 作者称该新方案不增加检查时间或费用,所得灌注参数与采用单独专用灌注方案的现有文献相当。

研究设计与样本

  • 可行性研究,57例胰腺导管腺癌患者在常规多期增强CT检查中接受CT灌注采集。
  • 使用160 mm宽覆盖256排CT扫描仪,静脉注射对比剂(4.2-5 ml/s)后5至42.5秒行灌注采集(15次采集,间隔2.5秒),随后行胰腺实质期和门静脉期用于临床判读。
  • 生成灌注图,采用去卷积算法计算肿瘤及未受累胰腺的血流量、血容量和渗透表面乘积,并与现有类似发表文献比较。
  • 记录辐射剂量信息,并根据体部尺寸计算体型特异性剂量估算值(SSDE)。

关键影像表现/征象

  • 肿瘤中心平均血流量为20.8 ± 12.1 ml/100 g/min,血容量为2.5 ± 2.1 ml/100 g,渗透表面乘积为15.5 ± 39.4 ml/100 g/min。
  • 未受累胰腺平均血流量为90.8 ± 50.2 ml/100 g/min,血容量为11.9 ± 4.3 ml/100 g,渗透表面乘积为33.6 ± 27.7 ml/100 g/min。

临床应用与阅片要点

  • 作者结论认为,该方案可在宽探测器256排CT上于常规胰腺分期或再分期CT中同期获得灌注定量参数,且不增加检查时间或费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the feasibility of CT perfusion performed during routine multiphase contrast-enhanced CT on a 160 mm wide-coverage 256-slice scanner in patients with pancreatic ductal adenocarcinoma (PDAC).

METHODS: Fifty-seven patients had a CT perfusion acquisition during their routine multiphase CT. Perfusion was performed 5 to 42.5 s (15 passes at 2.5 s intervals) after intravenous contrast administration (4.2-5 ml/s), followed by pancreatic parenchymal and portal venous phases for clinical interpretation. Perfusion maps were generated and blood flow (BF), blood volume (BV), and permeability surface area product (PS) for tumor and uninvolved pancreas were calculated using deconvolution algorithms and compared to existing similar publications. Radiation dose information was recorded and size-specific dose estimate (SSDE) was calculated using body dimensions.

RESULTS: Diagnostic quality of standard images was unaffected by performing the perfusion acquisition. Average tumor center BF was 20.8 ± 12.1 ml/100 g/min, BV 2.5 ± 2.1 ml/100 g and PS 15.5 ± 39.4 ml/100 g/min. Average pancreas BF was 90.8 ± 50.2 ml/100 g/min, BV 11.9 ± 4.3 ml/100 g and PS 33.6 ± 27.7 ml/100 g/min. For the perfusion acquisition, mean SSDE was 57 ± 11 mGy, CTDIvol 43 ± 6 mGy and DLP 685 ± 100 mGy-cm.

CONCLUSION: Adding a perfusion CT acquisition to standard pancreatic CT protocol is feasible using a wide-detector 256-slice CT scanner and adds quantitative information while maintaining diagnostic quality of the standard of care examination. This novel protocol adds no time or cost to the examination and yields perfusion parameters that are comparable to existing literature using a separate dedicated perfusion protocol.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. O'Malley RB, Soloff EV, Coveler AL, et al. Feasibility of wide detector CT perfusion imaging performed during routine staging and restaging of pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2020. PMID: 33079256. doi:10.1007/s00261-020-02786-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。